AstraZeneca PLC

AZN

GB0009895292

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-04-28 - Roadshow - Day 1

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

149.3 USD

Average target price

164.3 USD

Spread / Average Target

+10.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+13.09%	231B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B
PFIZER, INC.	-11.77%	144B

Other Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 03:13:58 2024-04-29 am EDT			5-day change	1st Jan Change
12,152 ^GBX	+1.37%		+9.52%	+13.09%

09:04am	AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study	MT
09:00am	AstraZeneca's Truqap Plus Faslodex Breast Cancer Treatment Bags EU Approval Recommendation	MT

AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study	03:04am	MT
AstraZeneca's Truqap Plus Faslodex Breast Cancer Treatment Bags EU Approval Recommendation	03:00am	MT
Hipgnosis Songs Fund backs new Blackstone bid	02:52am	AN
ASTRAZENECA : DZ Bank sticks Neutral	Apr. 26	ZD
ASTRAZENECA : UBS keeps a Sell rating	Apr. 26	ZD
ASTRAZENECA : Deutsche Bank remains Neutral	Apr. 26	ZD
ASTRAZENECA : Gets a Buy rating from Barclays	Apr. 26	ZD
Barclays Raises AstraZeneca PT, Affirms at Overweight	Apr. 26	MT
Peel Hunt cuts ConvaTec to 'reduce'	Apr. 26	AN
THE FTSE 100 is on a roll	Apr. 26
Health Care Drops Amid Mixed Earnings -- Health Care Roundup	Apr. 25	DJ
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 25	MT
Sector Update: Health Care Stocks Drop in Afternoon Trading	Apr. 25	MT
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump	Apr. 25	MT
ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade	Apr. 25
FTSE 100 shakes off red-hot US inflation gauge	Apr. 25	AN
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...	Apr. 25
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
ASTRAZENECA : UBS maintains a Sell rating	Apr. 25	ZD
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday	Apr. 25	MT
The specter of stagflation rears its ugly head again	Apr. 25
Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15	Apr. 25	DP
Sector Update: Health Care	Apr. 25	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Economic Data	Apr. 25	MT
ASTRAZENECA : Jefferies sticks Neutral	Apr. 25	ZD